MeiraGTx Holdings Inked A Asset Purchase Agreement With Janssen Pharmaceuticals For Acquiring Remaining Stake In Botaretigene Sparoparvovec (Bota-vec) For The Treatment Of X-linked Retinitis Pigmentosa (XLRP) For $415M
Author: Benzinga Newsdesk | December 21, 2023 08:05am